What Factors Propelled The Growth Of The Pentavalent Market In The Past?
The pentavalent market has seen considerable growth due to a variety of factors.
• In recent times, there has been a consistent growth in the size of the pentavalent market. It is projected to increase from $2.62 billion in 2024 to $2.73 billion in 2025 with a 4.4% compound annual growth rate (CAGR). The previous growth could be attributed to various factors such as global immunization drives, government-run vaccination programs, prevention of various diseases, public health awareness, as well as international collaborations and funding.
What is the Forecasted Market Size and CAGR for the Pentavalent Market?
The pentavalent market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for pentavalent is anticipated to experience consistent expansion in the coming years, reaching the value of $3.31 billion in 2029 with a compound annual growth rate (CAGR) of 5.0%.
Factors contributing to this growth over the forecast period include persistent worldwide vaccination efforts, growth of vaccine programs, entry into new regions, research and development activities, and partnership endeavors for vaccine availability. The forecast period will also witness significant trends such as global health strategies and financial assistance, campaigns for public education and awareness, government policies and regulations, and advancements in vaccine production technology.
What Are The Primary Growth Drivers In The Pentavalent Market?
The increasing occurrence of diphtheria is anticipated to drive the expansion of the pentavalent market. Diphtheria, caused by the bacterium Corynebacterium diphtheriae, is a very contagious, severe disease that can lead to great difficulty in eating and breathing, and even result in skin ulcers. The pentavalent vaccine aids in protecting children against this disease through a three-dose schedule of pentavalent immunization, thereby leading to an increased demand for these vaccines due to the rising occurrences of diphtheria. For example, in 2022, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported an unusually high count of diphtheria cases, primarily in June and August, through the International Health Regulations (IHR) reporting procedure. Seven countries have reported 144 cases of diphtheria, a large number of which are among refugees. Out of the 144 cases, 97 (69%) were determined to be clinically compatible, 44 (31%) were confirmed as toxigenic diphtheria cases by laboratory tests, and 3 (2%) were suspected cases. Consequently, the increasing instance of diphtheria is fuelling the growth of the pentavalent market.
What Are The Principal Market Segments In The Global Pentavalent Healthcare Industry?
The pentavalent market covered in this report is segmented –
1) By Type: Sodium Stibogluconate, Meglumine Antimoniate
2) By Formulation Type: Lyophilized, Liquid
3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Sodium Stibogluconate: Injectable Form, Oral Form, Other Formulations
2) By Meglumine Antimoniate: Injectable Form, Oral Form, Other Formulations
Pre-Book The Pentavalent Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Pentavalent Market?
The significant trend emerging in the pentavalent market revolves around product innovation. Numerous giant corporations in the market are creating novel items to bolster their market stance. For instance, in December 2022, Pfizer, which is an American pharmaceutical firm active in the pentavalent vaccine market, received endorsement from the US Food and Drug Administration, a US federal agency within the Health and Human Services Department, for their experimental pentavalent meningococcal vaccine candidate (MenABCWY) for adolescents. This is designed to prevent meningococcal disease in people aged between 10 and 25. The exceptional characteristic of the MenABCWY vaccine merges the components of two separate vaccines into one, offering protection against the meningococcal serogroups responsible for most invasive meningococcal diseases.
Who Are the Key Players in the Pentavalent Market?
Major companies operating in the pentavalent market include:
• Pfizer Inc.
• Merck & Co Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Shandong Xinhua Pharmaceutical Company Limited
• PT Bio Farma (Persero)
• Shantha Biotechnics Limited
• Biological E. Limited
• Serum Institute of India Private Limited
• Indian Immunologicals Limited. Incepta Pharmaceuticals Limited
• Shanghai Institute of Biological Products Co Ltd.
• Changchun Changsheng Biotechnology Co Ltd.
• Adimmune Corporation
• AJ Vaccines
• Albert David Limited
• PanGen Biotech Inc.
• Bharat Biotech International Limited
• Vacsera Ltd.
• Pasteur Institute of India
• Zydus Cadila Healthcare Limited
• EuBiologics Co Ltd.
What are the Regional Insights into the Pentavalent Market?
Asia-Pacific was the largest region in the pentavalent market in 2024. The regions covered in the pentavalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
